Pedestrians walk past the company logo of Dainippon Sumitomo Pharma Co., Ltd., at its offices in Tokyo, Japan, on Thursday, Sept. 3, 3009. Dainippon Sumitomo Pharma Co. will buy Sepracor Inc. for $2.6 billion, gaining a U.S. sales force and experimental treatments in the worldÕs biggest drug market. Photographer: Kimimasa Mayama/Bloomberg
Sunovion Pharmaceuticals Inc., a Marlborough-based subsidiary of Japanese drugmaker Sumitomo Dainippon Pharma Co. Ltd., will lay off 360 employees come January.
That's according to a notice the company filed with the state in order to comply with the Worker Adjustment and Retraining Act. The cuts are expected to take place on Jan. 13.
Copyright Boston Business Journal
